 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S. Food Drug Administration FDA has granted Fast Track Designation to the Companys lead candidate DM199 for the treatment of acute ischemic stroke AIS where tissue plasminogen activator andor mechanical thrombectomy are not indicated or medically appropria 